GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kopran Ltd (BOM:524280) » Definitions » Cyclically Adjusted Revenue per Share

Kopran (BOM:524280) Cyclically Adjusted Revenue per Share : ₹117.98 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Kopran Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kopran's adjusted revenue per share for the three months ended in Mar. 2025 was ₹35.622. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹117.98 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Kopran's average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kopran was 4.90% per year. The lowest was 4.90% per year. And the median was 4.90% per year.

As of today (2025-05-31), Kopran's current stock price is ₹182.75. Kopran's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹117.98. Kopran's Cyclically Adjusted PS Ratio of today is 1.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kopran was 3.22. The lowest was 0.94. And the median was 2.04.


Kopran Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Kopran's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kopran Cyclically Adjusted Revenue per Share Chart

Kopran Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 102.29 109.33 114.79 117.98

Kopran Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 114.79 116.40 117.11 117.93 117.98

Competitive Comparison of Kopran's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Kopran's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kopran's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kopran's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kopran's Cyclically Adjusted PS Ratio falls into.


;
;

Kopran Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kopran's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=35.622/157.5517*157.5517
=35.622

Current CPI (Mar. 2025) = 157.5517.

Kopran Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 14.372 99.841 22.679
201509 19.474 101.753 30.153
201512 18.452 102.901 28.252
201603 18.341 102.518 28.187
201606 14.551 105.961 21.636
201609 18.141 105.961 26.974
201612 18.376 105.196 27.522
201703 22.369 105.196 33.502
201706 11.858 107.109 17.443
201709 16.916 109.021 24.446
201712 21.850 109.404 31.466
201803 22.257 109.786 31.940
201806 13.820 111.317 19.560
201809 21.233 115.142 29.054
201812 24.373 115.142 33.350
201903 20.916 118.202 27.879
201906 18.936 120.880 24.681
201909 20.264 123.175 25.919
201912 23.168 126.235 28.916
202003 18.069 124.705 22.828
202006 27.946 127.000 34.669
202009 27.476 130.118 33.269
202012 25.892 130.889 31.166
202103 29.917 131.771 35.770
202106 17.420 134.084 20.469
202109 29.483 135.847 34.194
202112 30.469 138.161 34.745
202203 28.953 138.822 32.859
202206 26.131 142.347 28.922
202209 24.383 144.661 26.556
202212 32.756 145.763 35.405
202303 30.645 146.865 32.875
202306 24.472 150.280 25.656
202309 31.583 151.492 32.846
202312 32.904 152.924 33.900
202403 38.557 153.035 39.695
202406 28.904 155.789 29.231
202409 31.404 157.882 31.338
202412 34.384 158.323 34.217
202503 35.622 157.552 35.622

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Kopran  (BOM:524280) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kopran's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=182.75/117.98
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kopran was 3.22. The lowest was 0.94. And the median was 2.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kopran Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kopran's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kopran Business Description

Industry
Traded in Other Exchanges
Address
Dr. E. Moses Road, 1076, Parijat House, Worli, Mumbai, MH, IND, 400 018
Kopran Ltd is an Indian based pharmaceutical company. It is engaged in manufacturing of Formulation (Finished Dosage Form) and Active Pharmaceutical Ingredients (API) i.e., Pharmaceuticals. It manufactures dosage forms including, tablets, capsules, dry powder, suspension, and injectables. Some of its product range includes antibiotics, cardiovascular, anti-diabetes, respiratory, pain management, and gastrointestinal. Geographically, it has a presence in India; South Africa; Ethiopia; Zambia; Egypt; Jordan and Rest of World.

Kopran Headlines

No Headlines